Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-103 bemarituzumab combination study in previously untreated advanced gastric or gastroesophageal junction cancer
jRCT2041220013Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of bemarituzumab in gastric cancer (GC) and esophagogastric junction cancer (4 arms), sponsored by Amgen. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants who experience a treatment-emergent adverse event and 1 more. Started May 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2041220013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220013.